By repairing gut mucosa, dampening systemic cytokine release, and modulating immune pathways, they help stabilize the gutbrain axisa key regulator of nocturnal comfort and sleep continuity
The SURMOUNT-1 trial: Those on tirzepatide GIP GLP-1 (Mounjaro) saw up to 20.9% reduction [2]
The Rest of Europe region, including Nordic countries, Eastern Europe, Belgium, Switzerland, and Austria, is anticipated to hold 16.6% in 2025, declining slightly to 16.3% by 2035, attributed to mixed growth patterns with strong expansion in some healthcare markets balanced by moderate growth in smaller countries implementing diabetes care development programs
Home test strips or vials change color when bacteria are present, which is useful for a fast check
GLP-1 analogues have shown promise in improving cardiovascular health by reducing the risk of heart disease in individuals with obesity and diabetes